|(what is this?)|
Adapalene/benzoyl peroxide is a prescription medication combination for the treatment of severe acne vulgaris; marketed by Galderma under the trade name Epiduo. Its trade name in Canada is TactuPump, where it was previously known as Tactuo. It consists of a combination of adapalene (0.1%) and benzoyl peroxide (2.5%) in a topical gel formulation. Meta-analysis of clinical trials has shown this combined therapy to be more effective than either of its ingredients by themselves.
People are advised to exercise caution in using Epiduo together with other skin products containing sulfur, resorcinol, or salicylic acid, or with medicated or abrasive dirts and cleansers. Skin products with high levels of alcohol or astringents should also be avoided. Using topical products with a strong drying effect in combination with Epiduo can increase irritation. The use of adapalene/benzoyl peroxide in combination with oral antibiotics (lymecycline) has been studied; the combination was well tolerated and showed an improved success rate compared to those receiving only antibiotics (47.6% vs. 33.7%, P = 0.002).
Commonly reported side effects include the following:
- "FDA OKs New Acne Gel Epiduo". Webmd.com. Retrieved 2012-01-25.
- "How Does Benzoyl Peroxide Work on Acne".
- Tan, Jerry; Gollnick, Harald p. M.; Loesche, Christian; Ma, Y. May; Gold, Linda Stein (August 2011). "Synergistic efficacy of adapalene 0.1%-benzoyl peroxide 2.5% in the treatment of 3855 acne vulgaris patients". Journal of Dermatological Treatment. 22 (4): 197–205. doi:10.3109/09546631003681094. PMID 20666678.
- "Full prescribing information" (PDF). Retrieved 2012-01-25.
- Dréno, B.; Kaufmann, R.; Talarico, S.; Torres Lozada, V.; Rodríguez-Castellanos, M.A.; Gómez-Flores, M.; De Maubeuge, J.; Berg, M.; Foley, P.; Sysa-Jedrzejowska, A.; Kerrouche, N.; Paliargues, F.; Bettoli, V. (August 2011). "Combination therapy with adapalene-benzoyl peroxide and oral lymecycline in the treatment of moderate to severe acne vulgaris: a multicentre, randomized, double-blind controlled study". British Journal of Dermatology. 165 (2): 383–390. doi:10.1111/j.1365-2133.2011.10374.x.